<4 X 104 white blood cells per 5 X 109 erythrocytes.
Preparation and Isolation of Soluble Antigen (Ag)-Antibody (Ab)-Complement (C) Complexes
(Ag:Ab:C). Ag:Ab complexes were prepared from bovine serum albumin (BSA) and heatinactivated guinea pig antiserum to BSA. Antibody was raised and the antigen/antibody ratio at equivalence was determined as previously described (5) . Anti-BSA was diluted sufficiently that when mixed with BSA at equivalence, no precipitate formed. Ag:Ab were prepared in fourfold antibody excess, so that, after reaction of Ag:Ab with serum, Ag:Ab:(] gave maximum percentage binding (~75%) to human erythrocytes (5, 6) .
125I-C3-1abeled Ag:Ab:C were prepared by mixing one vol of Ag:Ab with an equal volume of 1:16 diluted normal human serum supplemented with x25I-C3 (10 ng/#l of 1:16 serum) and with the I-inhibitor K76 monocarboxylic acid (K76COOH) (26) , a gift from Dr. Kozo Inoue, Osaka University, Japan, at a final concentration of 4 mM. After incubation at 37°(] for 30 min, the reaction mixture was diluted twofold with ice-cold DOVB.
Ag:Ab:C bearing 125I-(]3 were separated from free 125I-C3 or (]3b and K76COOH by gel filtration through Biogel A1.5m (Bio-Rad Laboratories) equilibrated with DVB at 4°C. A typical elution profile is shown in Fig. 1 , together with an elution profile of z25I-BSA-labeled Ag:Ab:(] for comparison. Ag:Ab:C eluted as a single symmetrical peak at the void volume. 80% of added label was recovered in this peak in the case of the I25I-BSA-labeled preparation. 50 #1 of individual column fractions was added to suspensions of human or sheep erythrocytes (2 × l0 s cells in DOVB), the mixtures were incubated at 37°(] for 15 min, and the cells were washed. Fractions containing Ag:Ab:C, giving high binding to human and low binding to sheep erythrocytes, were pooled and used immediately. (27) . 3.75% stacking and 5-15% gradient running gels were used in most cases. A pool of proteins from a commercial kit (Bethesda Research Laboratories, Inc., Rockville, MD) was used to estimate the molecular 16 diluted serum supplemented with 1251-C3 and K76COOH, as described in Materials and Methods, was applied to a 2 × 100-cm column containing Biogel A1.5m equilibrated with DVB, and 500-~1 fractions were collected. The elution pattern (O) is shown along with the elution pattern (0) of a control reaction mixture obtained after identical incubation of ]25I-BSA-labeled Ag:Ab with untreated 1:16 diluted serum. In the latter case, >80% of the BSA label was recovered in the void volume. 50 btl aliquots of individual column fractions of ]~sI-C3-1abeled Ag:Ab:C were incubated at 37°C for 10 min with human or sheep erythrocytes (HUE, ShE) and, after washing, percentage binding was determined.
SDS-PAGE. SDS-PAGE was performed as described by Laemmli
weights of samples run under reducing conditions. Rabbit IgG, F(ab')2, Fab, and bovine albumin were used as molecular weight markers when samples were analyzed under nonreducing conditions. After electrophoresis, gels were stained with Coomassie blue or with the silver staining kit (Upjohn Diagnostics, Kalamazoo, MI). Radioautography was carried out at -70°C using X-Omat R film (XR-5, Eastman Kodak Co., Rochester, NY). In some instances, proteins were eluted from bands excised from the acrylamide gels, using the technique described in ref.
28.

Two-Dimensional Electrophoresis.
A modified O'Farrell technique (29) was used as described (30) . Electrofocussing was performed in the first dimension. A mixture ofAmpholines, pH 3-10, 5 8, and 9 11 (LKB Instruments, Inc., Rockville, MD), was used to obtain a pH range of from 5.1 to 9.1 The second dimension (SDS-PAGE) was carried out in a 5 15% gradient gel. The slab gels were then subjected to radioautography.
Results
Ability of Purified CR1 + I to Release C3 Fragments from EAC1423b. Because previous studies had shown that C3 fragments produced during release of Ag:Ab:C from human erythrocytes by I differed from those obtained after exposure of fluid phase C3b to ! + H or to I + CR1, the effects of each of these factors on C3b* were compared using the cell intermediate EAC1423b prepared with 125I-C3 and bearing five hemolytic sites per cell. Cells (10S/ml in DGVB, containing ~0.13 ~g of C3b*/ ml) were mixed at 30°C with I (2/~g/ml), CR1 (100 ng/ml), or H (5/~g/ml), or with mixtures of I + H or I + CR1 at the same final concentrations. At various time intervals (from 5 to 50 min) duplicate 100-~1 samples of each mixture were removed, mixed with 2 ml of ice-cold DGVB, and centrifuged at 600g for 10 min. In one set of samples, the radioactivity in the pellets and supernatants was counted in a gamma counter. In the other set, the residual hemolytic activity of EAC 1423b was measured. The results (Fig. 2 a) show that within a few minutes of incubation of EAC1423b with I + H or with I + CRx or CR1 alone, C3 hemolytic activity was abolished. The results agree with previous findings that I + H can transform EAC1423b into hemolytically inactive EAC1423bi (9, 15) and that CR~ alone can inhibit EAC1423b hemolytic sites (31) .
In contrast, as shown in Fig. 2 b, only ! + CR1 released large amounts of C3 fragments from the cells. At 30 min of incubation with I + CR1 ~70% of the C3 radioactivity was found in the supernatant, whereas <10% was specifically released by I or by I + H. Under the same conditions, we incubated EAC14 cells bearing five hemolytic sites per cell and prepared with radiolabeled C4, with I (2 ~g/ml) + CR1 (100 ng/ml), or with I + C4bp (1 ~g/ml). The amount of radioactivity released in the supernatant during 1 h of incubation at 30°C was negligible and not significantly different from that released from cells incubated with buffer alone.
In a separate experiment (not shown), we studied the effects of the concentration of I and CR1 on the release of C3 fragments from the EAC1423b cells. The extent of release was higher as the concentration of either reagent was increased. Moreover, when the dose of CR1 was diminished, the release could be enhanced by an increase in the dose of I and vice versa. 12% of the C3b* counts were released specifically from cells incubated for 30 min at 30°C with 12.5 ng/ml of CR1 and 4/~g/ml of I. About 9% release was observed in the presence of 125 ~g/ml of H and 12.5 /~g/ml of I. Considering that the molecular weights of the subunits of CR1 and H are ~200,000 and 150,000, respectively, on a molar basis, the CR1 activity is at least 104 greater than that of H.
Effect of Membrane-associated CR1 on C3b* in the Presence of I. The effects of isolated
CR1 and membrane-associated CR1 on EAC 1423b are compared in Fig. 3 . EAC 1423b (10S/ml) and I (2/xg/ml) were incubated at 30°C for 30 min with increasing numbers of washed human erythrocytes or with the equivalent amounts of purified CR1 (400 ng/109 human erythrocytes) (12) , and the reaction was terminated as described above. As shown, C3 fragments were released from EAC1423b by both human erythrocytes and purified CR1 in a dose-dependent fashion. Moreover, the specific activities of the intact erythrocytes and purified CR1 were almost identical. That the human erythrocyte activity was mediated exclusively by CRa was shown by its complete inhibition in the presence of 2 #g/ml of pooled purified monoclonal antibodies to CRa.
Evidence That iC3b* Is a Ligand for CRI. Previous observations have shown that
CR1 + I or H + I cleave the a' chain of fluid-phase C3b and generate iC3b. One trivial explanation for the finding that CR~ + I but not H + I can fragment C3b* beyond the iC3b* stage is that CRI is contaminated by a proteolytic enzyme. Alternatively, the reaction between C3b*, CR], and I could proceed in two steps, both requiring CR1.
To distinguish between these possibilities, we studied the activity of CR1 + I on the intermediate EAC 1423bi prepared with radiolabeled C3. To prepare EAC 1423bi, we incubated EAC 1423b with I + H, as described in Materials and Methods, and washed the cells by centrifugation. Hemolytic assays showed no residual C3b* sites, and direct analysis by SDS-PAGE of the hydroxylamine-treated membranes of these cells demonstrated that the a' chain of C3b* had been cleaved (inset of Fig. 4) .
The EAC1423bi were then incubated at 37°C in the presence of buffer, I, CR1, or CR1 + I. In the presence of CR1 + I (but not CR1 or I alone) C3 fragments were released in the supernatant (Fig. 4) . Moreover, release also occurred when the cells were first exposed to CR1 alone, washed thoroughly, and then incubated with I. That the release was CR1 mediated was shown by its complete inhibition when monoclonal antibodies to CR1 (5/~g/ml) were added to the incubation medium. As an additional control, other tubes containing EAC1423bi were incubated with plasmin. In this instance, the release of C3 fragments could not be inhibited by the monoclonal antibodies. These results demonstrate that EAC 1423bi has binding affinity for CR1 and that the further degradation of iC3b* in the presence of I is CR1 dependent.
Structure of the Fragments Released by CR1 + I from EAC1423b
. The C3 fragments released in the supernatant of the reaction between EAC 1423b with CR1 + I or with human erythrocytes + I were analyzed by SDS-PAGE. No significant variation was observed in their structure when the time of incubation at 30°C varied from 5 to 75 min. As shown in Fig. 5 , their apparent molecular weight was ~135 K under nonreducing conditions. After reduction, two main labeled polypeptides were detected: JR chain and a fragment with an apparent molecular weight of 31,000, most likely derived from the a' chain (Fig. 6 ). When gels were overexposed, weak 70-K and 40-K bands were observed. The structure of the fragments released in small amounts by H + I was identical (data not shown).
The 135-K fragment was further identified as C3c because it could be specifically immunoprecipitated with an antiserum to C3c but not to C3d. Moreover, the 31-K polypeptide isolated from bands excised from the slab gels also reacted with anti-C3c.
FIc. 4. Release of C3 fragments from EAC1423bi by CR1 + I or plasmin. EAC1423bi (10 s cells/ ml) were incubated with plasmin (10 #g/ml), or CR1 (400 ng/ml) or CR1 + I (4/.tg/ml) in the presence or absence of anti-CR1 (5 #g/ml) at 30°C. Alternatively, EACI423bi were first incubated with CR1 for 30 min at 30°C, washed thoroughly, and used for the kinetic studies of C3 release by I alone. At timed intervals, 100 ~1 of reaction mixtures were withdrawn into tubes with 2 ml ice-cold DGVB, centrifuged, and the radioactivity in pellets and supernatants counted. In the figure, the symbol / represents a washing step before the addition of reagent (s) to the erythrocyte intermediate. The results demonstrate that CRa interacts with EAC 1423bi and that C3bi* can be further cleaved in the presence of I. That the activity is mediated by CR1 itself and not a contaminant enzyme is shown by the inhibition of the reaction with monoclonal antibodies to the receptor. As expected, the monoclonals did not interfere with the activity of plasmin. The inset of this figure contains the SDS-PAGE analysis of the membranes of the EAC 1423b and EAC 1423bi cells, prepared as described in Materials and Methods. After treatment with H + I, the a' chain of C3b was cleaved.
(These antisera were directed against fragments purified from elastase-digests of C3.)
Possible explanations for the discrepancy between the molecular weight of C3c under n o n r e d u c i n g conditions (135,000) a n d the molecular weights of the major observed bands (75 K a n d 31 K) u n d e r reducing conditions are that the 3 I-K b a n d represents two polypeptide chains or that C3c contains a weakly labeled peptide. T h e 31-K peptide could not be resolved by two-dimensional electrophoretic analysis, a n d its pI was found to be 8.6. In other experiments, we analyzed supernatants originating from EAC1423b cells prepared with 100 times more C3. Silver stain of the gels revealed two C3-derived bands at 39 K and 42 K (not shown).
The breakdown products released by plasmin are also shown in Figs. 5 a n d 6 because this enzyme has been used frequently by others to generate C3c a n d C3d fragments. Clearly, the C3c fragments obtained with plasmin a n d with CR1 + I differ greatly in structure. U n e r n o n r e d u c i n g conditions, some free fl chain was detected in the plasmin C3c, but the m a i n fragment had an ~6 6 -K tool wt. U n d e r reducing conditions, three peptides were detected of 75 K (,8 chain), 60 K, a n d 27 K tool wt. It should be pointed out that plasmin cleaves the fl chain of fluid-phase iC3b (32) . T h a t plasmin probably also cleaves the fl chain of fluid-phase iC3b* is shown in Fig.  6 : the intensity of the fl chain b a n d in track CR1 + I is stronger than that of plasmin + H + I .
In addition, Fig. 6 shows the products obtained by i n c u b a t i o n of radiolabeled fluidphase C3b with I + CR1 or I + H. As expected (10, 11) , the 70-K a n d 40-K fragments Fro. 5. SDS-PAGE analysis under nonreducing conditions of the cleavage products released from cell-bound C3b*. EAC1423b (108 cells/ml), prepared with radiolabeled C3 and bearing three hemolytic sites per cell, were incubated with I (2/.tg/ml) + H (5/lg/ml) for 60 min at 30°C, washed, and further incubated with plasmin (10 ~g/ml) for 60 rain. The EACI423b cells were also incubated with I (2 lag/ml) + CR, (100 ng/ml) or with I + human erythrocytes (2.5 × 108 cells/ml) for 60 min at 30°C. The cells were centrifuged and the supernatants were analyzed by SDS-PAGE under nonreducing conditions and radioautography. The positions of rabbit IgG and its fragments and of BSA in the stained gel are indicated. It is apparent that the main fragment released by CRI + I or human erythrocytes + I, has a molecular weight o f -135,000. Moreover, its structure differs from that of the fragment resulting from the activity of plasmin on EAC1423bi.
of the a' chain were generated. W h e n the radioautographs were overexposed, faint 39-K and 31-K bands were observed in the tracks c o n t a i n i n g the product of the reaction between CR1 + I a n d C3b. The 39-K radiolabeled peptide a n d the 39-K silver stained b a n d found u p o n SDS-PAGE of C3c may be identical. This peptide may be poorly labeled when C3 rather than C3b is radioiodinated (33) .
Ability of CR1 + I to Cleave C3 Bound to Soluble Ag:Ab:C.
Soluble BSA-anti-BSA-C complexes bearing radiolabeled C3 fragments were purified as described in Materials and Methods. About 80% of the C3 associated with these complexes b o u n d to the surface m e m b r a n e of h u m a n erythrocytes but not to sheep erythrocytes. T h e b i n d i n g was CR1 mediated because treatment of the h u m a n erythrocytes with 50 n g / m l of pooled monoclonal anti-CRj antibody before addition of Ag:Ab:C completely abolished binding, and treatment with 4 btg/m[ anti-CR1 after b i n d i n g released >50% of Ag:Ab:C.
The following experiment was performed to determine whether isolated CR1 could serve the function of intact erythrocytes (7) in the I-associated cleavage of the C3 b o u n d to the Ag:Ab:C and to compare its effect to that of H. Aliquots of 125I-C3-labeled Ag:Ab:C were incubated at 37°C for 30 min with DOVB, I, H, CR1, H + I, CRa + I, or h u m a n erythrocytes + I. Samples of each reaction mixture were then subjected to SDS-PAGE under reducing conditions, and the radioautograph patterns were compared (Fig. 7) .
Fie. 6. SDS-PAGE analysis under reducing conditions of cleavage products released from cellbound C3b*. The supernatants, obtained as described in the legend of Fig. 4 , are analyzed here under reducing conditions. In addition, for comparison, we analyzed the cleavage products of fluid phase C3b by I + H and I + CR1. For this purpose, radiolabeled C3b (0.25 #g/ml) was incubated for 3 h at 37°C with I (2/.tg/ml) + CR~ (200 ng/ml) or with I + H (20/.tg/ml). The results show that the fragment released frona EAC 1423b by CR] 4-I contains mainly radiolabeled fl chain and a 31-K peptide. The structure of the fragment released by plasmin is quite different, and contains some fl chain, a 60-K, and a 27-K peptide. The intensity of the fl chain band is reduced, suggesting that it was broken down by the activity of plasmin. The treatment of fluid-phase C3b resulted in the cleavage of the a' chain into 70-K and 40-K polypeptides. 39-K and 31-K polypeptides could be seen in the radioautographs of the tracks containing the reaction products of CR1 4-I with fluidphase C3b when the radioautograph was overexposed (data not shown).
Fxo. 7. SDS-PAGE analysis of cleavage products of C3 after treatment of soluble immune complexes with H, I, CR1, and human erythrocytes, a2sI-C3-1abeled Ag:Ab:C were incubated at 37°C for 30 rain with DOVB, I alone (1.6 pg), H alone (32 pg), or CR] alone (0.16 pg) or I (1.6/Lg) + H (32/~g) or CR~ 0.0025 pg or 0.04 #g) + I (0.1 /.tg or 1.6 #g) or HuE (6 X 106 or l0 s ) + I (0.1 pg or 1.6 pg) in a total volume of 150 pl. Samples of each reaction mixture were assessed by SDS-PAGE 5-15% gradient gels under reducing conditions, followed by radioautography. Aliquots of 125I-C3-1abeled Ag:Ab:C were added to equal volumes of a solution of I (2 btg/ml) + CR1 (50 ng/ml) and incubated at 37°C. Reactions were stopped after various times by addition of K76COOH (4 mM) and transfer to ice. Samples were subjected to SDS-PAGE 5-15% gradient gels under reducing conditions, followed by radioautography. More conspicuous modifications occurred when the complexes were treated with CR1 + I: the intensity of the high tool wt C3 bands diminished, and simultaneously a 31-K b a n d appeared. T h e intensity of the 31-K b a n d was dependent on the dose of CRx and I. W h e n the concentration of I was decreased, a 36-K b a n d was also observed in the radioautographs, suggesting that it may be an intermediate product. The degradation of C3 was even more pronounced after incubation with h u m a n erythrocytes + I. At the highest concentration of erythrocytes + I, little radioactivity remained at the top of the gel, and the b a n d at 31-K was most prominent (track on the right side of Fig. 7) . The radioactivity remaining on top of the gel could represent C3d* fragments of the a' chain covalently associated with constituents of the Ag:Ab:C.
Next, we studied the time-course of a p p e a r a n c e of the 31-K peptide. Separate aliquots of 125I-C3-1abeled A g : A b : C were a d d e d to equal volumes of a solution of I ( 2 / t g / m l ) + CR1 (200 ng/ml), the mixtures placed at 37°C, and reactions stopped after various times (from 0.5 to 30 rain) by addition of K 7 6 C O O H (final concentration, 4 raM) and transfer to ice. Samples of each reaction mixture were subjected to SDS-PAGE, and r a d i o a u t o g r a p h patterns were analyzed.
As seen in Fig, 8 , within 0.5 rain of incubation, some 31-K peptide was generated. Its intensity as well as that of other peptides (70-K, 40-K, and 36-K) increased progressively during the incubation. At the same time, there was a decrease in intensity of the high tool wt bands.
In short, these experiments confirm previous observations (7, 8) that human erythrocytes and I can cleave C3" associated with Ag:Ab:C beyond the iC3b* stage and show that the cleavage is CRa dependent. Also, from the comparison in Fig. 7 of the effects of H (32 #g) + I (1.6 #g) with CR1 (0.0025 #g) + I, (0.1 #g) we conclude that, on a molar basis, CRa is at least 2 × 104 times more efficient than H in the degradation of C3 peptides bound to the Ag:Ab:C. As in the case of iC3b* associated with cell membranes, a 31-K peptide is generated during this interaction. The precise pathway of degradation of the a' chain ofiC3b* is not evident from these experiments. Although the results indicate that the 31-K band is an end product of the reaction and that the 36-K peptide could represent an intermediate, this interpretation requires further investigation.
Discussion
The mechanisms of C3b inactivation have been studied extensively. Both fluidphase C3b and C3b* can be cleaved by I. The former reaction requires H, and the latter can be enhanced by H (9, 10) . In this process, the a' chain is cleaved into major fragments of apparent 70 K and 40 K tool wt. Both fluid-phase iC3b and iC3b* can be further cleaved in vitro by plasmin, elastase, or trypsin, but the physiological relevance of the breakdown products has remained conjectural (32, 37, 38) . It is also known that further degradation of iC3b* occurs slowly in serum. Fearon (11) has shown that CR1 can replace H in the cleavage of fluid-phase C3b to C3bi. Recently, some of us have shown (7) that release of C3c from soluble IC is mediated by I and dependent on binding to human erythrocytes. Moreover, in serum this reaction occurs independent of H. Medicus and Arnaout (39) have also reported that breakdown of iC3b* can be I-mediated in a reaction that was greatly enhanced by human erythrocytes.
Here we show directly that the human erythrocyte factor mediating this effect is CR1. In the presence of I + purified CR1 or I + human erythrocytes, C3b* associated with EAC 1423b was cleaved into C3c and C3d*. Generation of C3c was inhibited in the presence of low concentrations of monoclonal antibodies to CR1. The C3c fragments released from EAC1423b and from Ag:Ab:C (7) have an ~135-K mol wt under nonreducing conditions. Upon reduction, major bands of 75 K (most likely fi chain) and 31K (pI 8.6) were detected by radioautography.
One possible interpretation is that C3c consists of fl chains, one 31-K a'-derived labeled peptide, and a second weakly radiolabeled peptide. The findings that twodimensional electrophoresis did not resolve the 31-K band and that two other bands at 39 K and 42 K not apparent in the radiographs were revealed in the slab gels by silver staining support this possibility. However, further studies are necessary to determine the precise structure of C3c, the number of cleavages involved in its production, and whether small mol wt degradation products of C3, some with biological activity (C3e, C3f, ref. [40] [41] [42] , are generated during the fragmentation of iC3b* by CR1 + I.
The studies with soluble Ag:Ab:C (Figs. 7, 8 ) suggest that iC3b* degradation is complex and that it may involve more than two steps with the formation of intermediates. Bands with the mobility of degradation products of fluid-phase C3b; that is, 70 K and 40 K, were found in variable amounts in different studies with soluble IC. These fragments could arise from noncovalent C3b*. Indeed, we found striking differences in the susceptibility to proteolysis by CRI + I of fluid-phase C3b and C3b*, in that C3c was effectively released only from the latter. For example, when 0.25/~g/ml of fluid-phase C3b were incubated for 3 h at 37°C with 200 ng/ml of CR1 and 2 btg/ml of I, the end product was mostly iC3b; only small amounts of the 39 K and 31 K fragments were formed (Fig. 6) . This is to be contrasted with the treatment of 0.13 ~g/ml of C3b* associated with cell membranes, in which case most or all of it was cleaved beyond iC3b*, and C3c released by 100 ng/ml of CR1 + 2/zg/ ml of I. The reasons for this difference are not clear but may relate to the nature of the bonds between C3b* and the IC, the clustering of C3b during the binding process (perhaps allowing the formation of muhivalent bonds with CR1), or the modulating activity of neighboring molecules from the IC.
Although some breakdown products can be released from C3b* by I + H, and their structure is similar to those generated by I + CR1, CR1 is between 104 and 10 ~ times more efficient than H in promoting fragmentation of C3b*. Considering that the concentration of H in blood is only about 125 times greater than CR1 (250/~g/ml vs. 2/xg/ml), the physiological breakdown of C3b* most likely takes place in solid phase; that is, on the surface of cells bearing CR1. This is supported by observations in vitro and in vivo. When soluble IC are added to human blood in vitro, they bind to various blood elements in proportion to their relative content of CR1 and thus associate predominantly with CR1 of erythrocytes (5). Incubation with serum factors (I + H) does not eliminate this interaction (8) . However, exposure to I of IC bound to human erythrocytes causes C3b breakdown and IC release. Similar processing of IC in other species may occur on other cells because a large proportion of Ag:Ab:C injected into mice fix complement in vivo and become rapidly associated with platelets that, in this species, bear the majority of C3b receptors (43) .
Of interest was the finding that CR1 promotes the cleavage of iC3b*. About 75% of the C3 label was released as C3c fragments when EAC 1423bi (prepared by treating EAC1423b with H + I) was further incubated with CR1 + I. The same amount of C3c was released when EAC1423bi was first treated with CR1, washed, and then incubated with I. The observations that EAC1423bi had no measurable hemolytic activity and that almost no intact a' chains were detected by SDS-PAGE on the stroma of EAC1423bi argue that the substrate of the CR1 activity was not residual uncleaved C3b* remaining on the cells. The simplest interpretation of these experiments is that CR1 can bind iC3b* and that the reaction between C3b*, CR1, and I CR1 + I CR1 + I proceeds in at least two steps: C3b* iC3b*--C3c + C3d*. A likely implication, therefore, is that CR1 also recognizes particles bearing iC3b*, a property that had been previously attributed exclusively to another membrane receptor, termed CR3, present on phagocytes as well as other cells (44) . Whether CRa recognizes other C3 degradation products (42, 45) requires further investigation.
Finally , the present results support the idea that CR1 is a membrane-associated regulatory protein (11, 31) whose function is to process IC in vivo (5) (6) (7) (8) and are probably of relevance to the understanding of the pathology of diseases associated with circulating IC. For example, patients with certain connective tissue diseases have a deficiency in CR1 on erythrocytes (12, 46) and kidney glomeruli (47, 48) . Whether this represents a primary abnormality or a secondary manifestation of the disease process, such a deficiency could lead to an impairment of inactivation of C3b* and contribute to perpetuation of inflammation.
Summary
The main finding of this paper is that CR1, the membrane receptor for C3b and C4b, together with C3b/C4b-inactivator (I), degrades C3b bound to immune complexes (C3b*). Two fragments are generated: C3c, which is released from the immune complexes, and C3d*. The C3c fragment released from the cell intermediate EAC 1423b prepared with 125I-C3 was analyzed by sodium dodecyl sulfate polyacrylamide gel electrnphoresis (SDS-PAGE) and radioautography. It has a 135,000 mol wt and contains disulfide bonded labeled polypeptide chains of 75,000 and 31,000 mol wt, which presumably represent the fl and a fragment of the a'-chain of C3b*. Silver staining of the SDS-PAGE gels revealed other C3-derived bands with 39-42,000 tool wt. Human erythrocytes + I also cleave C3b* into C3c and C3d*. The activity of the erythrocytes is CR1 mediated because it can be totally inhibited by monoclonal antibodies to CR1.
In contrast with these results, I together with the serum protein/~IH (H) transform EAC1423b into hemolytically inactive EAC1423bi and cleave the a' chain of C3b* into fragments of 70,000 and 40,000 mol wt. Small amounts of C3c are also released at relatively high concentrations of H. On a molar basis, the efficiency of CR1 in the generation of C3c and C3d is 104-105 greater than H.
An additional observation was that C3c could be released by treating EAC1423bi with CRa + I and that this reaction was also inhibited by monoclonal antibodies to CR1. Therefore, it is likely that CR1 has binding affinity for iC3b and that the I + CR1 I + CRa degradation of C3b* proceeds as follows: C3b*--iC3b*--C3c + C3d*. Taken together, our findings argue that the processing of C3b* in vivo occurs in solid phase, that is, on the surface of cells bearing CR1.
Note added in proof" During the preparation of this manuscript, Medicus et al. found that polyclonal anti-CR1 antibody also blocks enhanced breakdown of iC3b* by human erythrocytes in the presence of I in their system (R. Medicus, personal communication).
